Bifidobacterium breve

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Bifidobacterium breve
Scientific classification
B. breve

Cleenwerck et al. 2002
Binomial name
Bifidobacterium breve

Bifidobacterium breve is a bacterial species of the genus Bifidobacterium which has probiotic properties.[1][2]

History and clinical uses[edit]

B. breve strains were originally isolated from the feces of human infants.[3] In 1971, Bifidobacterium parvulorum and Bifidobacterium breve were merged under the name Bifidobacterium breve.[3] Bifidobacterim breve administered in combination with prebiotics or other probiotics and standard therapy has showed some beneficial effect.[4] B. breve is a constituent in the therapeutic, nutritional treatment VSL#3. This proprietary, standardized, formulation of live bacteria is used to treat ulcerative colitis and may require a prescription.[4][5]


B. breve strains can ferment mannitol and sorbitol, but not arabinose or xylose.[3]


  1. ^ Lyra, A.; Krogius-Kurikka, L.; Nikkilä, J.; Malinen, E.; Kajander, K.; Kurikka, K.; Korpela, R.; Palva, A. (2010). "Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. It has a lot of probiotic advantages". BMC Gastroenterol. 10: 110. doi:10.1186/1471-230X-10-110. PMC 2949774. PMID 20849659.
  2. ^ Tabbers, M.; de Milliano, I.; Roseboom, M.; Benninga, M. (2011). "Is Bifidobacterium breve effective in the treatment of childhood constipation? Results from a pilot study". Nutrition Journal. 10: 19. doi:10.1186/1475-2891-10-19.
  3. ^ a b c Scardovi V; Trovatelli LD; Zani G; Crociani F; Matteuzzi D (October 1971). "Deoxyribonucleic Acid Homology Relationships Among Species of the Genus Bifidobacterium". Int J Syst Evol Microbiol. 21: 276–294. doi:10.1099/00207713-21-4-276.
  4. ^ a b Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW (Dec 9, 2014). "Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease". Clin Exp Gastroenterol (Review). 7: 473–87. doi:10.2147/CEG.S27530. PMC 4266241. PMID 25525379.
  5. ^ Saez-Lara, Maria Jose; Gomez-Llorente, Carolina; Plaza-Diaz, Julio; Gil, Angel (2015). "The Role of Probiotic Lactic Acid Bacteria and Bifidobacteria in the Prevention and Treatment of Inflammatory Bowel Disease and Other Related Diseases: A Systematic Review of Randomized Human Clinical Trials". BioMed Research International. 2015: 1–15. doi:10.1155/2015/505878. ISSN 2314-6133. PMC 4352483. PMID 25793197.

External links[edit]